Introduction Nils Kessel, Joseph Gabriel, David Herzberg Part One: Systematizing Risk and Benefit1. Such Immoral Pharmacy: Pharmacists, Physicians, and Addressing the Harms and Benefits of Secret Remedies in Canada Dan Malleck 2. Ehrlich's Dangerous Magic: Salvarsan and the Fantasy of Pharmaceutical Innovation Joseph Gabriel 3. A Non-Linear History of Side Effects: Risk Management, Pharmaceutical Innovation, and WHO's Adverse Drug Reaction Monitoring, 1945-1980 Nils Kessel Part Two: Narrating Risk and Benefit4. What's in a Substance? LSD and the Impending Decline of the West Beat B ächi 5. Hallucinations: 1960s Filmic Narratives of Subjective Lived Psychedelic Experiences and their Legal/Illegal Status Christian Bonah 6. Proscribing and Prescribing: Drug Education in 1980s Britain Alex Mold Part Three: Crises of Risk and Benefit7. Depo-Provera and Medical Controversies in Britain 1970s-1980s Caroline Rusterholz 8.

Trivializing an Extra-ordinary Analgesic: The Example of Tramadol in General Practice Josephine Eberhart 9. Change for Continuity: Temporalities of Risk and Benefit in the French Appetite Suppressant Scandal of Mediator® (1976-2009) Solène Lellinger Part Four: Resisting Systems of Risk and Benefit10. Lying about Opioids? Rescuing Risk and Benefit from the Addiction Paradigm David Herzberg 11. "Why Must We Again Be the Guinea Pigs in this Genocidal Mentality?": Toward a Historical Understanding of Black Popular Resistance to Harm Reduction Samuel Kelton Roberts 12. When Abstinence is Risk: Naloxone's Path to Over-the-Counter Status Nancy D. Campbell Part Five: Consumer Paradigms of Risk and Benefit 13. "A Healthy Reactive Tendency": Risks and Benefits of Cannabis and User Agency in the 1930s Bob Beach 14. When is an Opioid Not an Opioid? Loperamide, the Use of Pharmacology and the Pharmacology of Use Jeremy Greene and Avery Gulino 15.

Containing a Gray Market Drug: The Rise and Regulation of the U.S. Poppers Industry, 1969-1991 Joseph Jay Sosa List of ContributorsIndex.